PURPOSE: To investigate genetic prothrombotic factors ( @entity5337 and @entity556 gene @entity14553 mutations) and their relation with @entity732 in ocular Beh  et disease. METHODS: Thirty Beh  et @entity1 were prospectively recruited into the study. Their mean age was 34.2 +/- 8.3 years. All @entity1 underwent complete ophthalmic examination and @entity941 angiography. Of the 30 @entity1 , 15 (16 eyes) had @entity732 . @entity1 were tested for the presence of @entity5337 and @entity556 gene @entity14553 mutations by polymerase chain reaction. The results were compared with the frequencies of @entity5337 in 285 and @entity556 gene @entity14553 mutation in 182 healthy members of the Turkish population. RESULTS: The prevalence of @entity5337 mutation was significantly higher in ocular Beh  et @entity1 (12/30, 40%), compared with healthy control subjects (28/285, 9.8%) (p < 0.001). Of the 12 Beh  et @entity1 with @entity5337 mutation, eight had @entity732 . The prevalence of @entity5337 was 53.3% (8/15) of the 15 @entity1 with @entity732 and 26.7% (4/15) of the remaining 15 @entity1 without @entity432 . @entity556 gene mutation was detected in none of Beh  et @entity1 compared with 2.7% (5/182) of the control group. CONCLUSION: These data suggest that @entity5337 may be an additional risk factor in ocular Beh  et disease, whereas factor II mutations do not seem to be relevant.

XXXX and @entity556 gene @entity14553 mutations in ocular Beh  et disease.

@entity5337 :: ('2153', 'Gene') :: ['factor V Leiden'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity556 :: ('2147', 'Gene') :: ['prothrombin', 'Prothrombin'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein'] @entity432 :: ('MESH:D001157', 'Disease') :: ['vascular occlusion'] @entity14553 :: ('c|SUB|G|20210|A', 'DNAMutation') :: ['G20210A'] @entity732 :: ('MESH:D015356', 'Disease') :: ['retinal vascular occlusion', 'retinal vascular occlusions']
@entity5337 :: (2153,Gene) :: ['Factor V Leiden']
